<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598208</url>
  </required_header>
  <id_info>
    <org_study_id>P06055</org_study_id>
    <secondary_id>38826</secondary_id>
    <nct_id>NCT00598208</nct_id>
  </id_info>
  <brief_title>A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)</brief_title>
  <official_title>A Phase 2, Open Label, Randomized Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or ICSI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate the dose -response relationship of a
      single injection of Org 38286 to initiate multifollicular growth for the first seven days in
      a controlled ovarian hyperstimulation (COH) protocol for IVF or ICSI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2003</start_date>
  <completion_date type="Actual">March 15, 2004</completion_date>
  <primary_completion_date type="Actual">March 15, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cumulus-oocyte-complexes retrieved</measure>
    <time_frame>1 cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment failure rate</measure>
    <time_frame>1 cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">325</enrollment>
  <condition>Fertilization</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 µg Org 36286 (corifollitropin alfa)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 µg Org 36286 (corifollitropin alfa)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 µg Org 36286 (corifollitropin alfa)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Follitropin beta injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corifollitropin alfa</intervention_name>
    <description>On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Org 36286</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin beta injection</intervention_name>
    <description>Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Follistim®</other_name>
    <other_name>Puregon®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females of couples with an indication for COH and IVF or ICSI;

          -  &gt;=18 and &lt;=39 years of age at the time of signing informed consent;

          -  BMI &gt;=18 and &lt;=29 kg/m^2;

          -  Normal menstrual cycle length: 24-35 days;

          -  Ejaculatory sperm (use of donated and/or frozen sperm is allowed);

          -  Willing and able to sign informed consent.

        Exclusion Criteria:

          -  History of/or any current (treated) endocrine abnormality;

          -  History of ovarian hyperstimulation syndrome (OHSS);

          -  History of/or current polycystic ovary syndrome (PCOS) or current polycystic ovaries
             according to USS (at least 10 follicles of 2-8 mm in each ovary);

          -  More than three unsuccessful COH cycles since the last established ongoing pregnancy
             (if applicable);

          -  History of non- or low ovarian response to FSH/hMG treatment;

          -  Any clinically relevant hormone value outside the reference range during the early
             follicular phase (menstrual cycle day 2-7) as measured by the local laboratory (FSH,
             LH, E2, P, total T, TSH and prolactin):

          -  Any clinically relevant abnormal laboratory value;

          -  Less than 2 ovaries;

          -  Any ovarian and/or abdominal abnormality interfering with ultrasound examination;

          -  Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation,
             undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);

          -  Epilepsy, diabetes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or
             abdominal disease;

          -  History of presence of alcohol or drug abuse within 12 months prior to signing
             informed consent;

          -  Previous use of Org 36286;

          -  Use of hormonal preparations within 1 month prior to randomization;

          -  Hypersensitivity to Org 32489 (Puregon®) and/or Org 37462 (Orgalutran®) and/or
             Pregnyl® or any of their components;

          -  Administration of investigational drugs within three months prior to signing informed
             consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2008</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In-vitro fertilization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

